Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia

D. Gothelf, A. Apter*, J. Reidman, A. Brand-Gothelf, Y. Bloch, G. Gal, L. Kikinzon, S. Tyano, R. Weizman, G. Ratzoni

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

56 Scopus citations


Objectives: To evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol. Methods: Forty-three patients were treated with olanzapine (n = 19), risperidone (n = 17) and haloperidol (n = 7) for 8 weeks in an open clinical trial. Clinical improvement was evaluated with the Positive and Negative Syndrome Scale (PANSS), and side effects with the Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale. Results: Significant clinical improvement was observed by week 4 for all medications. Olanzapine and haloperidol induced fatigability more frequently than risperidone. Haloperidol was associated with a higher frequency of depression and more severe extrapyramidal symptoms. Conclusions: To the best of our knowledge this is the first study in adolescents to compare the efficacy and side effects of three most commonly prescribed antipsychotic medications. Olanzapine, risperidone and haloperidol appear to be equally effective for the treatment of schizophrenia in adolescent inpatients but have different side effect profiles.

Original languageEnglish
Pages (from-to)545-560
Number of pages16
JournalJournal of Neural Transmission
Issue number5
StatePublished - 1 May 2003
Externally publishedYes


  • Adolescents
  • Antipsychotics
  • Haloperidol
  • Olanzapine
  • Risperidone
  • Side effects

Cite this